This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorn, L. D. Articles by Chrousos, G. P. Search for Related Content PubMed PubMed Citation Articles by Dorn, L. D. Articles by Chrousos, G. P.

The Longitudinal Course of Psychopathology in Cushing’s Syndrome after Correction of Hypercortisolism

School of Nursing, University of Pittsburgh (L.D.D.), Pittsburgh, Pennsylvania 15261; Developmental Endocrinology Branch, National Institute of Child Health and Human Development (L.D.D., G.P.C.), and the Departments of Behavioral Pediatrics (B.D.) and Clinical Neuroendocrinology (P.W.G.), National Institute of Mental Health, Bethesda, Maryland 20892; Butler Hospital, Brown University (E.S.B.), Providence, Rhode Island 02912; and Cedar-Sinai Medical Center (T.C.F.), Los Angeles, California 90048

Address all correspondence and requests for reprints to: Dr. L. D. Dorn, University of Pittsburgh, School of Nursing, Pittsburgh, Pennsylvania 15261.

Endogenous Cushing’s syndrome (CS) is associated with significant psychopathology during the course of the disease. The purpose of this study was to evaluate the psychological and endocrine status of patients with CS after correction of their hypercortisolism. Thirty-three patients with active CS were examined before and at 3 months (28 patients), 6 months (25 patients), and 12 months (29 patients) after correction of hypercortisolism. Before cure, 66.7% of the patients had significant psychopathology, with the predominant diagnosis of atypical depressive disorder (AD) in 51.5% and/or major affective disorder in 12%. After cure, overall psychopathology decreased significantly to 53.6% at 3 months, 36% at 6 months, and 24.1% at 12 months, when there was a parallel recovery of the hypothalamic-pituitary-adrenal axis assessed by serial morning ACTH stimulation tests. There was an inverse correlation between psychological recovery and baseline morning cortisol, but no correlation with ACTH-stimulated cortisol values at 60 min. AD continued to be the prevailing diagnosis after correction of hypercortisolism, whereas the frequency of suicidal ideation and panic increased. The presence of AD before and after correction of hypercortisolism might be due to glucocorticoid-induced suppression of hypothalamic CRH secretion. The slight increase in the incidence of panic after correction of hypercortisolism might be due to a decreased glucocorticoid restraint at the central arousal/sympathetic catecholaminergic system. We conclude that CS is associated with AD symptomatology, which gradually improves with time after correction of hypercortisolism. Health care providers should be aware of changes in symptomatology, including suicidal ideation and panic attacks, that occur in a subgroup of patients.

This article has been cited by other articles:

				S M Webb, X Badia, M J Barahona, A Colao, C J Strasburger, A Tabarin, M O van Aken, R Pivonello, G Stalla, S W J Lamberts, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire Eur. J. Endocrinol., May 1, 2008; 158(5): 623 - 630. [Abstract] [Full Text] [PDF]

				L F Chan, H L Storr, P N Plowman, L A Perry, G M Besser, A B Grossman, and M O Savage Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy Eur. J. Endocrinol., April 1, 2007; 156(4): 477 - 482. [Abstract] [Full Text] [PDF]

				J. R. Lindsay, T. Nansel, S. Baid, J. Gumowski, and L. K. Nieman Long-Term Impaired Quality of Life in Cushing's Syndrome despite Initial Improvement after Surgical Remission J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 447 - 453. [Abstract] [Full Text] [PDF]

				M. O. van Aken, A. M. Pereira, N. R. Biermasz, S. W. van Thiel, H. C. Hoftijzer, J. W. A. Smit, F. Roelfsema, S. W. J. Lamberts, and J. A. Romijn Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3279 - 3286. [Abstract] [Full Text] [PDF]

				D. P. Merke, J. N. Giedd, M. F. Keil, S. L. Mehlinger, E. A. Wiggs, S. Holzer, E. Rawson, A. C. Vaituzis, C. A. Stratakis, and G. P. Chrousos Children Experience Cognitive Decline Despite Reversal of Brain Atrophy One Year After Resolution of Cushing Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2531 - 2536. [Abstract] [Full Text] [PDF]

				A. Alkemade, U. A. Unmehopa, W. M. Wiersinga, D. F. Swaab, and E. Fliers Glucocorticoids Decrease Thyrotropin-Releasing Hormone Messenger Ribonucleic Acid Expression in the Paraventricular Nucleus of the Human Hypothalamus J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 323 - 327. [Abstract] [Full Text] [PDF]

				G. P. Chrousos Is 11{beta}-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? PNAS, April 27, 2004; 101(17): 6329 - 6330. [Full Text] [PDF]

				G. Arnaldi, A. Angeli, A. B. Atkinson, X. Bertagna, F. Cavagnini, G. P. Chrousos, G. A. Fava, J. W. Findling, R. C. Gaillard, A. B. Grossman, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5593 - 5602. [Abstract] [Full Text] [PDF]

				Z.'e. Hochberg, K. Pacak, and G. P. Chrousos Endocrine Withdrawal Syndromes Endocr. Rev., August 1, 2003; 24(4): 523 - 538. [Abstract] [Full Text] [PDF]

				I. Bourdeau, C. Bard, B. Noel, I. Leclerc, M.-P. Cordeau, M. Belair, J. Lesage, L. Lafontaine, and A. Lacroix Loss of Brain Volume in Endogenous Cushing's Syndrome and Its Reversibility after Correction of Hypercortisolism J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1949 - 1954. [Abstract] [Full Text] [PDF]

				J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3568 - 3573. [Abstract] [Full Text] [PDF]

				L. D. Dorn and P. Cerrone Cognitive Function in Patients with Cushing Syndrome: A Longitudinal Perspective Clin Nurs Res, November 1, 2000; 9(4): 420 - 440. [Abstract] [PDF]

				P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]

				E. R. de Kloet, E. Vreugdenhil, M. S. Oitzl, and M. Joëls Brain Corticosteroid Receptor Balance in Health and Disease Endocr. Rev., June 1, 1998; 19(3): 269 - 301. [Abstract] [Full Text]